Trialbee, a global technology provider for patient matching and engagement in clinical trials, has announced a partnership with Clinerion, a worldwide medical data informatics company with a global research network comprised of 30.2 million patients online across 69 healthcare organizations in 15 countries. This partnership will aim to accelerate time to market by shortening patient recruitment and enrollment timelines and will reduce costs associated with patient recruitment and loss-to-follow-up.
“This partnership significantly broadens our global reach and allows us to expand our data set for predictable intelligence-based patient recruitment and retention to support traditional and decentralized trials,” said Lollo Eriksson, CEO of Trialbee. “This is a great opportunity for both organizations to make trials simpler for investigators and to deliver on our commitment of expediting clinical research by optimizing the use of real-world data.”
More than 80% of trials are delayed and approximately 30% of sites never enroll patients because of limited access to patients who match the study criteria. The Trialbee platform provides full transparency of the status of the referred patient flow throughout the entire clinical trial and continuously offers sites and sponsors full insight into the effectiveness of recruitment strategies.
Read the full release, here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.